Literature DB >> 28285093

Associations of central aortic pressure and brachial blood pressure with flow mediated dilatation in apparently healthy Japanese men: The Circulatory Risk in Communities Study (CIRCS).

Keyang Liu1, Renzhe Cui1, Ehab S Eshak2, Meishan Cui1, Jia-Yi Dong1, Masahiko Kiyama3, Takeo Okada3, Akihiko Kitamura4, Mitsumasa Umesawa5, Kazumasa Yamagishi6, Hironori Imano1, Tetsuya Ohira7, Hiroyasu Iso8.   

Abstract

BACKGROUND AND AIMS: Endothelial dysfunction is considered the first stage in the development of atherosclerosis and cardiovascular disease, and brachial flow-mediated dilation (FMD) is a measure of endothelial function. It is uncertain which of central systolic aortic pressure (CAP) or brachial systolic blood pressure (SBP) is more strongly associated with FMD. Therefore, we examined the correlations of CAP and SBP with FMD in Japanese men.
METHODS: The study subjects comprised 507 male volunteers aged 30-79 years that were residents in two communities under the Circulatory Risk in Communities Study (CIRCS) between 2013 and 2015. The low percent change of FMD (%FMD) ≤5.0%, after 5 min of reactive hyperemia evaluated by the brachial artery diameter, was used to assess endothelial dysfunction. Values of CAP and SBP were divided into tertiles, with the lowest tertile used as a reference.
RESULTS: After adjustment for cardiovascular risk factors, the multivariable odds ratio (95% CI) of low FMD for the highest versus lowest tertile of CAP was 1.5 (0.9-2.6) for total subjects and 1.4 (0.5-3.8) for those with, and 2.4 (1.2-4.8) for those without antihypertensive medication use. The corresponding odd ratios for the highest versus lowest tertile of SBP were 0.9 (0.5-1.5), 0.8 (0.3-2.2), and 1.3 (0.7-2.5), respectively.
CONCLUSIONS: Higher CAP levels were associated with low FMD for men without antihypertensive medication, but such an association was not found for SBP levels.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Central aortic pressure; Cross sectional study; Endothelial function; Japanese men

Mesh:

Substances:

Year:  2017        PMID: 28285093     DOI: 10.1016/j.atherosclerosis.2017.02.024

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  5 in total

1.  Association between Serum Uric Acid and Impaired Endothelial Function: The Circulatory Risk in Communities Study.

Authors:  Jingyun Tang; Keyang Liu; Ehab S Eshak; Renzhe Cui; Ryoto Sakaniwa; Hironori Imano; Jia-Yi Dong; Hiroyasu Iso
Journal:  J Atheroscler Thromb       Date:  2021-12-01       Impact factor: 4.394

2.  Impact of pulsed electromagnetic field therapy on vascular function and blood pressure in hypertensive individuals.

Authors:  Glenn M Stewart; Courtney M Wheatley-Guy; Bruce D Johnson; Win K Shen; Chul-Ho Kim
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-05-13       Impact factor: 3.738

3.  Age- and sex-related profiles for macro, macro/micro and microvascular reactivity indexes: Association between indexes and normative data from 2609 healthy subjects (3-85 years).

Authors:  Yanina Zócalo; Daniel Bia
Journal:  PLoS One       Date:  2021-07-19       Impact factor: 3.240

4.  Associations of Tobacco Smoking with Impaired Endothelial Function: The Circulatory Risk in Communities Study (CIRCS).

Authors:  Meishan Cui; Renzhe Cui; Keyang Liu; Jia-Yi Dong; Hironori Imano; Mina Hayama-Terada; Isao Muraki; Masahiko Kiyama; Takeo Okada; Akihiko Kitamura; Mitsumasa Umesawa; Kazumasa Yamagishi; Tetsuya Ohira; Hiroyasu Iso
Journal:  J Atheroscler Thromb       Date:  2018-02-08       Impact factor: 4.928

5.  Relationship between Endothelial Dysfunction and Prevalence of Chronic Kidney Disease: The Circulatory Risk in Communities Study (CIRCS).

Authors:  Yuting Li; Renzhe Cui; Keyang Liu; Ehab S Eshak; Meishan Cui; Jiayi Dong; Hironori Imano; Isao Muraki; Masahiko Kiyama; Akihiko Kitamura; Takeo Okada; Kazumasa Yamagishi; Mitsumasa Umesawa; Tetsuya Ohira; Hiroyasu Iso
Journal:  J Atheroscler Thromb       Date:  2020-09-02       Impact factor: 4.928

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.